For example, even among non-small cell lung cancer (NSCLC) patients with classic EGFR mutations, where exon 19 deletions and L858R exon 21 point mutations account for 90% of EGFR mutations, response rates have ranged from 58 to 85% in phase IIb/III clinical trials evaluating anti-EGFR tyrosine kinase inhibitors (e.g., Erlotinib, Gefitinib, Afatinib, Osimertinib)4–11. Here, EGFR is linked to non-small cell lung carcinoma.